Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
Read More
2 minute read

European Medicines Agency’s Committee for Medicinal Products for Human Use Recommended Approval of Dupixent for Children Aged 6 to 11 Years with Severe Asthma with Type 2 Inflammation

By Charles Gross
Today, 7:04 AM
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending to extend the approval of Dupixent® (dupilumab) in the European Union (EU) to include add-on maintenance treatment for children aged 6 to 11 years with severe asthma with type 2 inflammation characterized by raised blood eosinophils and/or raised fractional exhaled nitr

REGN

Read More
4 minute read

Analysis: Why Is It So Difficult To Obtain COVID-19 Monoclonal Antibody Treatments?

By Phil Hall
Today, 7:04 AM
The demand for monoclonal antibody treatments to help in the recovery of COVID-19 patients has outpaced the supply, and this situation runs the risk of becoming more acute as federal regulators consider whether to limit the authorization of certain treatments that have yet to show their efficacy in mitigating the fast-spreading omicron variant. 

AZN